首页 > 最新文献

Advances In Anatomic Pathology最新文献

英文 中文
Laryngectomy Margin Assessment: A Little Help From a Template. 喉切除术边缘评估:模板的一点帮助。
IF 5.1 2区 医学 Q1 PATHOLOGY Pub Date : 2024-10-31 DOI: 10.1097/PAP.0000000000000471
Daniel J Zaccarini, Lester D R Thompson

Laryngectomy margin assessment is an important part of patient care and can affect outcomes. There is no standard approach to grossing laryngectomy specimens, with variations in the published guidelines. A uniform approach to margin assessment may be helpful to improve patient care and future research. At the very least, sampling of all mucosal margins (arytenoid area, hypopharyngeal, and anterior epiglottis) and tracheal margin should be performed. Sampling of soft tissue margins may be delegated to the pathologist, and contingent on the tumor extent into soft tissue. If a tracheostomy is present, skin and soft tissue margins should be sampled from the stoma. This review provides a template for laryngectomy margin assessment and can be used as a guideline as to which margins should be assessed.

喉切除术边缘评估是患者护理的重要组成部分,会影响治疗效果。喉切除术标本的毛细处理没有标准方法,已出版的指南也不尽相同。统一的边缘评估方法可能有助于改善患者护理和未来研究。至少应该对所有粘膜边缘(杓状区、下咽和会厌前部)和气管边缘进行取样。软组织边缘的取样可委托病理学家进行,并取决于肿瘤向软组织延伸的范围。如果存在气管造口,则应从造口处采集皮肤和软组织边缘样本。本综述为喉切除术边缘评估提供了一个模板,可作为评估哪些边缘的指南。
{"title":"Laryngectomy Margin Assessment: A Little Help From a Template.","authors":"Daniel J Zaccarini, Lester D R Thompson","doi":"10.1097/PAP.0000000000000471","DOIUrl":"https://doi.org/10.1097/PAP.0000000000000471","url":null,"abstract":"<p><p>Laryngectomy margin assessment is an important part of patient care and can affect outcomes. There is no standard approach to grossing laryngectomy specimens, with variations in the published guidelines. A uniform approach to margin assessment may be helpful to improve patient care and future research. At the very least, sampling of all mucosal margins (arytenoid area, hypopharyngeal, and anterior epiglottis) and tracheal margin should be performed. Sampling of soft tissue margins may be delegated to the pathologist, and contingent on the tumor extent into soft tissue. If a tracheostomy is present, skin and soft tissue margins should be sampled from the stoma. This review provides a template for laryngectomy margin assessment and can be used as a guideline as to which margins should be assessed.</p>","PeriodicalId":7305,"journal":{"name":"Advances In Anatomic Pathology","volume":" ","pages":""},"PeriodicalIF":5.1,"publicationDate":"2024-10-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142556885","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Lipomatous Neoplasms of Soft Tissue: A Contemporary Review. 软组织脂肪瘤:当代回顾。
IF 5.1 2区 医学 Q1 PATHOLOGY Pub Date : 2024-10-22 DOI: 10.1097/PAP.0000000000000468
Kshitij Arora, Andrew E Rosenberg

This review summarizes the clinicopathologic features of various lipomatous tumors of soft tissue and addresses some recent conceptual issues relating to adipocytic neoplasms, such as atypical spindle cell/pleomorphic lipomatous tumor and myxoid pleomorphic liposarcoma, and provides an update on the molecular aspects of these tumors. Recent advances in cytogenetic characterization and classification of lipomatous tumors are reviewed, and the genetic importance of distinct chromosomal aberrations are briefly discussed.

这篇综述总结了各种软组织脂肪瘤的临床病理特征,探讨了与脂肪细胞肿瘤(如非典型纺锤形细胞/多形性脂肪瘤和肌样多形性脂肪肉瘤)有关的一些最新概念问题,并提供了这些肿瘤在分子方面的最新进展。文章回顾了脂肪瘤细胞遗传学特征描述和分类的最新进展,并简要讨论了不同染色体畸变的遗传重要性。
{"title":"Lipomatous Neoplasms of Soft Tissue: A Contemporary Review.","authors":"Kshitij Arora, Andrew E Rosenberg","doi":"10.1097/PAP.0000000000000468","DOIUrl":"https://doi.org/10.1097/PAP.0000000000000468","url":null,"abstract":"<p><p>This review summarizes the clinicopathologic features of various lipomatous tumors of soft tissue and addresses some recent conceptual issues relating to adipocytic neoplasms, such as atypical spindle cell/pleomorphic lipomatous tumor and myxoid pleomorphic liposarcoma, and provides an update on the molecular aspects of these tumors. Recent advances in cytogenetic characterization and classification of lipomatous tumors are reviewed, and the genetic importance of distinct chromosomal aberrations are briefly discussed.</p>","PeriodicalId":7305,"journal":{"name":"Advances In Anatomic Pathology","volume":" ","pages":""},"PeriodicalIF":5.1,"publicationDate":"2024-10-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142455706","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Molecularly Defined Thoracic Neoplasms. 分子定义的胸部肿瘤。
IF 5.1 2区 医学 Q1 PATHOLOGY Pub Date : 2024-09-01 Epub Date: 2024-03-19 DOI: 10.1097/PAP.0000000000000439
Anja C Roden

Molecularly defined neoplasms are increasingly recognized, given the broader application and performance of molecular studies. These studies allow us to better characterize these neoplasms and learn about their pathogenesis. In the thorax, molecularly defined neoplasms include tumors such as NUT carcinoma, SMARCA4-deficient undifferentiated tumor (DUT), primary pulmonary myxoid sarcoma with EWSR1::CREB1 fusion, hyalinizing clear cell carcinoma, and SMARCB1-deficient neoplasms. Overall, these tumors are rare but are now more often recognized given more widely available immunostains such as NUT (NUT carcinoma), BRG1 (SMARCA4-DUT), and INI-1 (SMARCB1-deficient neoplasm). Furthermore, cytogenetic studies for EWSR1 to support a hyalinizing clear cell carcinoma or primary pulmonary myxoid sarcoma are, in general, easily accessible. This enables pathologists to recognize and diagnose these tumors. The diagnosis of these tumors is important for clinical management and treatment. For instance, clinical trials are available for patients with NUT carcinoma, SMARCA4-DUT, and SMACRB1-deficient neoplasms. Herein, our current knowledge of clinical, morphologic, immunophenotypic, and molecular features of NUT carcinomas, SMARCA4-DUT, primary pulmonary myxoid sarcomas, hyalinizing clear cell carcinoma, and SMARCB1-deficient neoplasms will be reviewed.

随着分子研究的广泛应用和性能的提高,分子定义的肿瘤越来越多地得到认可。这些研究使我们能够更好地描述这些肿瘤的特征并了解其发病机制。在胸部,分子定义肿瘤包括 NUT 癌、SMARCA4 缺陷未分化肿瘤(DUT)、EWSR1::CREB1 融合原发性肺肌样肉瘤、透明透明细胞癌和 SMARCB1 缺陷肿瘤。总的来说,这些肿瘤比较罕见,但由于现在有了更广泛的免疫标记物,如 NUT(NUT 癌)、BRG1(SMARCA4-DUT)和 INI-1(SMARCB1 缺失性肿瘤),因此更容易识别。此外,EWSR1 的细胞遗传学研究支持透明透明细胞癌或原发性肺 myxoid 肉瘤,这在一般情况下很容易获得。这使病理学家能够识别和诊断这些肿瘤。这些肿瘤的诊断对临床管理和治疗非常重要。例如,NUT 癌、SMARCA4-DUT 和 SMACRB1 缺失性肿瘤患者可进行临床试验。在此,我们将对 NUT 癌、SMARCA4-DUT、原发性肺肌样肉瘤、透明透明细胞癌和 SMARCB1 缺失性肿瘤的临床、形态学、免疫表型和分子特征的现有知识进行回顾。
{"title":"Molecularly Defined Thoracic Neoplasms.","authors":"Anja C Roden","doi":"10.1097/PAP.0000000000000439","DOIUrl":"10.1097/PAP.0000000000000439","url":null,"abstract":"<p><p>Molecularly defined neoplasms are increasingly recognized, given the broader application and performance of molecular studies. These studies allow us to better characterize these neoplasms and learn about their pathogenesis. In the thorax, molecularly defined neoplasms include tumors such as NUT carcinoma, SMARCA4-deficient undifferentiated tumor (DUT), primary pulmonary myxoid sarcoma with EWSR1::CREB1 fusion, hyalinizing clear cell carcinoma, and SMARCB1-deficient neoplasms. Overall, these tumors are rare but are now more often recognized given more widely available immunostains such as NUT (NUT carcinoma), BRG1 (SMARCA4-DUT), and INI-1 (SMARCB1-deficient neoplasm). Furthermore, cytogenetic studies for EWSR1 to support a hyalinizing clear cell carcinoma or primary pulmonary myxoid sarcoma are, in general, easily accessible. This enables pathologists to recognize and diagnose these tumors. The diagnosis of these tumors is important for clinical management and treatment. For instance, clinical trials are available for patients with NUT carcinoma, SMARCA4-DUT, and SMACRB1-deficient neoplasms. Herein, our current knowledge of clinical, morphologic, immunophenotypic, and molecular features of NUT carcinomas, SMARCA4-DUT, primary pulmonary myxoid sarcomas, hyalinizing clear cell carcinoma, and SMARCB1-deficient neoplasms will be reviewed.</p>","PeriodicalId":7305,"journal":{"name":"Advances In Anatomic Pathology","volume":" ","pages":"303-317"},"PeriodicalIF":5.1,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140157284","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Artificial Intelligence and Lung Pathology. 人工智能与肺部病理学
IF 5.1 2区 医学 Q1 PATHOLOGY Pub Date : 2024-09-01 Epub Date: 2024-05-23 DOI: 10.1097/PAP.0000000000000448
Emanuel Caranfil, Kris Lami, Wataru Uegami, Junya Fukuoka

This manuscript provides a comprehensive overview of the application of artificial intelligence (AI) in lung pathology, particularly in the diagnosis of lung cancer. It discusses various AI models designed to support pathologists and clinicians. AI models supporting pathologists are to standardize diagnosis, score PD-L1 status, supporting tumor cellularity count, and indicating explainability for pathologic judgements. Several models predict outcomes beyond pathologic diagnosis and predict clinical outcomes like patients' survival and molecular alterations. The manuscript emphasizes the potential of AI to enhance accuracy and efficiency in pathology, while also addressing the challenges and future directions for integrating AI into clinical practice.

本手稿全面概述了人工智能(AI)在肺病理学中的应用,尤其是在肺癌诊断中的应用。它讨论了各种旨在支持病理学家和临床医生的人工智能模型。为病理学家提供支持的人工智能模型包括标准化诊断、PD-L1 状态评分、支持肿瘤细胞计数以及显示病理判断的可解释性。一些模型预测病理诊断以外的结果,并预测临床结果,如患者的生存和分子改变。手稿强调了人工智能在提高病理诊断准确性和效率方面的潜力,同时也探讨了将人工智能融入临床实践的挑战和未来方向。
{"title":"Artificial Intelligence and Lung Pathology.","authors":"Emanuel Caranfil, Kris Lami, Wataru Uegami, Junya Fukuoka","doi":"10.1097/PAP.0000000000000448","DOIUrl":"10.1097/PAP.0000000000000448","url":null,"abstract":"<p><p>This manuscript provides a comprehensive overview of the application of artificial intelligence (AI) in lung pathology, particularly in the diagnosis of lung cancer. It discusses various AI models designed to support pathologists and clinicians. AI models supporting pathologists are to standardize diagnosis, score PD-L1 status, supporting tumor cellularity count, and indicating explainability for pathologic judgements. Several models predict outcomes beyond pathologic diagnosis and predict clinical outcomes like patients' survival and molecular alterations. The manuscript emphasizes the potential of AI to enhance accuracy and efficiency in pathology, while also addressing the challenges and future directions for integrating AI into clinical practice.</p>","PeriodicalId":7305,"journal":{"name":"Advances In Anatomic Pathology","volume":" ","pages":"344-351"},"PeriodicalIF":5.1,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141080275","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Morphologic Features of Invasion in Lung Adenocarcinoma: Diagnostic Pitfalls. 肺腺癌侵袭的形态学特征:诊断陷阱。
IF 5.1 2区 医学 Q1 PATHOLOGY Pub Date : 2024-09-01 Epub Date: 2024-05-13 DOI: 10.1097/PAP.0000000000000451
Erik Thunnissen, Masayuki Noguchi, Sabina Berezowska, Mauro Giulio Papotti, Federica Filipello, Yuko Minami, Hans Blaauwgeers

Reproducibility of pulmonary invasive adenocarcinoma diagnosis is poor when applying the World Health Organization (WHO) classification. In this article, we aimed first to explain by 3-dimensional morphology why simple pattern recognition induces pitfalls for the assessment of invasion as applied in the current WHO classification of pulmonary adenocarcinomas. The underlying iatrogenic-induced morphologic alterations in collapsed adenocarcinoma in situ overlap with criteria for invasive adenocarcinoma. Pitfalls in seemingly acinar and papillary carcinoma are addressed with additional cytokeratin 7 and elastin stains. In addition, we provide more stringent criteria for a better reproducible and likely generalizable classification.

采用世界卫生组织(WHO)的分类方法诊断肺浸润性腺癌的再现性很差。在本文中,我们首先旨在通过三维形态学来解释为什么简单的模式识别会导致目前世界卫生组织(WHO)肺腺癌分类中的侵袭评估出现误区。塌陷性原位腺癌潜在的先天性形态改变与浸润性腺癌的标准重叠。此外,我们还采用细胞角蛋白 7 和弹性蛋白染色法,解决了看似尖状癌和乳头状癌的误区。此外,我们还提供了更严格的标准,以提高分类的可重复性和通用性。
{"title":"Morphologic Features of Invasion in Lung Adenocarcinoma: Diagnostic Pitfalls.","authors":"Erik Thunnissen, Masayuki Noguchi, Sabina Berezowska, Mauro Giulio Papotti, Federica Filipello, Yuko Minami, Hans Blaauwgeers","doi":"10.1097/PAP.0000000000000451","DOIUrl":"10.1097/PAP.0000000000000451","url":null,"abstract":"<p><p>Reproducibility of pulmonary invasive adenocarcinoma diagnosis is poor when applying the World Health Organization (WHO) classification. In this article, we aimed first to explain by 3-dimensional morphology why simple pattern recognition induces pitfalls for the assessment of invasion as applied in the current WHO classification of pulmonary adenocarcinomas. The underlying iatrogenic-induced morphologic alterations in collapsed adenocarcinoma in situ overlap with criteria for invasive adenocarcinoma. Pitfalls in seemingly acinar and papillary carcinoma are addressed with additional cytokeratin 7 and elastin stains. In addition, we provide more stringent criteria for a better reproducible and likely generalizable classification.</p>","PeriodicalId":7305,"journal":{"name":"Advances In Anatomic Pathology","volume":" ","pages":"289-302"},"PeriodicalIF":5.1,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140911343","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
From Morphology to Molecules: Advances in the Distinction of Multiple Primary Lung Cancers From Intrapulmonary Metastases in Non-Small Cell Lung Cancer. 从形态到分子:非小细胞肺癌多原发肺癌与肺内转移瘤的鉴别进展。
IF 5.1 2区 医学 Q1 PATHOLOGY Pub Date : 2024-09-01 Epub Date: 2024-05-08 DOI: 10.1097/PAP.0000000000000449
Gheorghe-Emilian Olteanu, Izidor Kern, Lipika Kalson, Luka Brcic

The increasing incidence of multiple lung nodules underscores the need for precise differentiation between multiple primary lung cancers (MPLCs) and intrapulmonary metastases (IPMs). This distinction impacts patient prognosis and treatment strategies. The prevalence of multiple lung nodules, ranging from 19.7% to 55.5%, highlights the clinical significance of this challenge. Historically, the role of histopathology, particularly comprehensive histology assessment (CHA), has been pivotal in differentiating MPLCs and IPMs. However, CHA has significant limitations, resulting in a constant search for a better way to distinguish those lesions. The best strategy for delineating MPLCs from IPMs is a multidisciplinary approach combining clinical data, radiology, histology, and molecular methods. Histology provides architectural and cellular characteristics, radiology contributes anatomic context and lesion characterization, and molecular methods reveal molecular features critical for accurate differentiation. Incorporating clinical data further enhances diagnostic precision. This review presents current knowledge and current approaches to multiple lung tumors. It is clear that even with a combination of pathology, radiology, and molecular data, definitive classification of multifocal lung tumors is not always possible.

多发性肺结节的发病率越来越高,这凸显了精确区分多发性原发性肺癌(MPLC)和肺内转移瘤(IPM)的必要性。这种区分会影响患者的预后和治疗策略。多发性肺结节的发病率从19.7%到55.5%不等,凸显了这一挑战的临床意义。从历史上看,组织病理学,尤其是综合组织学评估(CHA)在区分 MPLC 和 IPM 方面发挥了关键作用。然而,组织病理学评估有很大的局限性,因此需要不断寻找更好的方法来区分这些病变。区分 MPLC 和 IPM 的最佳策略是结合临床数据、放射学、组织学和分子方法的多学科方法。组织学可提供结构和细胞特征,放射学可提供解剖背景和病变特征,分子方法可揭示对准确区分至关重要的分子特征。结合临床数据可进一步提高诊断的精确性。本综述介绍了目前对多发性肺肿瘤的认识和方法。显然,即使结合病理学、放射学和分子数据,也不一定能对多灶性肺肿瘤进行明确分类。
{"title":"From Morphology to Molecules: Advances in the Distinction of Multiple Primary Lung Cancers From Intrapulmonary Metastases in Non-Small Cell Lung Cancer.","authors":"Gheorghe-Emilian Olteanu, Izidor Kern, Lipika Kalson, Luka Brcic","doi":"10.1097/PAP.0000000000000449","DOIUrl":"10.1097/PAP.0000000000000449","url":null,"abstract":"<p><p>The increasing incidence of multiple lung nodules underscores the need for precise differentiation between multiple primary lung cancers (MPLCs) and intrapulmonary metastases (IPMs). This distinction impacts patient prognosis and treatment strategies. The prevalence of multiple lung nodules, ranging from 19.7% to 55.5%, highlights the clinical significance of this challenge. Historically, the role of histopathology, particularly comprehensive histology assessment (CHA), has been pivotal in differentiating MPLCs and IPMs. However, CHA has significant limitations, resulting in a constant search for a better way to distinguish those lesions. The best strategy for delineating MPLCs from IPMs is a multidisciplinary approach combining clinical data, radiology, histology, and molecular methods. Histology provides architectural and cellular characteristics, radiology contributes anatomic context and lesion characterization, and molecular methods reveal molecular features critical for accurate differentiation. Incorporating clinical data further enhances diagnostic precision. This review presents current knowledge and current approaches to multiple lung tumors. It is clear that even with a combination of pathology, radiology, and molecular data, definitive classification of multifocal lung tumors is not always possible.</p>","PeriodicalId":7305,"journal":{"name":"Advances In Anatomic Pathology","volume":" ","pages":"318-323"},"PeriodicalIF":5.1,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140875512","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Challenges in Thoracic Pathology. 胸部病理学的挑战。
IF 5.1 2区 医学 Q1 PATHOLOGY Pub Date : 2024-09-01 Epub Date: 2024-07-08 DOI: 10.1097/PAP.0000000000000456
Sanja Dacic, Luka Brcic
{"title":"Challenges in Thoracic Pathology.","authors":"Sanja Dacic, Luka Brcic","doi":"10.1097/PAP.0000000000000456","DOIUrl":"10.1097/PAP.0000000000000456","url":null,"abstract":"","PeriodicalId":7305,"journal":{"name":"Advances In Anatomic Pathology","volume":" ","pages":"281-282"},"PeriodicalIF":5.1,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141554012","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Clinicopathologic Features of Primary Immunodeficiency Monogenic Disease-related Very Early Onset Inflammatory Bowel Disease: Focus on Gastrointestinal Histologic Features in IFIH1 Mutations. 原发性免疫缺陷单基因病相关极早发炎症性肠病的临床病理特征:聚焦IFIH1突变的胃肠道组织学特征。
IF 5.1 2区 医学 Q1 PATHOLOGY Pub Date : 2024-08-14 DOI: 10.1097/PAP.0000000000000457
Luisa Santoro, Federica Grillo, Maria D'Armiento, Anna Maria Buccoliero, Michele Rocco, Jacopo Ferro, Alessandro Vanoli, Barbara Cafferata, Maria Cristina Macciomei, Claudia Mescoli, Mara Cananzi, Rita Alaggio, Matteo Fassan, Luca Mastracci, Paola Francalanci, Paola Parente

Very early onset inflammatory bowel disease (VEO-IBD) is a clinical term referring to IBD-like symptomatology arising in children younger than 6 years. VEO-IBD may be due to polygenic etiology in "pure" IBD (Crohn disease-CD and ulcerative colitis-UC), or it may be caused by primary immunodeficiency underlined by monogenic disease. Primary immunodeficiency monogenic diseases have a Mendelian inheritance and affect the immune system with multiorgan morbidity and possible effects on the gastrointestinal system. Primary Immunodeficiency monogenic diseases differ from "pure" IBD as the latter primarily affect the gastrointestinal tract with mitigated extraintestinal symptomatology. Since their first description, primary immunodeficiency monogenic diseases, although rare, have been the subject of increasing interest due to their dramatic phenotype, difficulty in reaching a timely diagnosis, and specific therapeutic approach. In this paper, we present a brief review of primary immunodeficiency monogenic diseases, focusing on to their clinicopathologic features as well as delving, in greater detail, into monogenic diseases caused by IFIH1 mutations. The clinicopathologic features of 4 patients with IFIH1, a gene involved in interferon pathway deficiency, will be described using a histologic pattern of damage approach confirming the need to avoid the histologic diagnosis of VEO-IBD in children younger than 6 years.

极早发炎症性肠病(VEO-IBD)是一个临床术语,指 6 岁以下儿童出现的类似 IBD 的症状。VEO-IBD 可能是由于 "纯 "IBD(克罗恩病-CD 和溃疡性结肠炎-UC)中的多基因病因所致,也可能是由单基因疾病强调的原发性免疫缺陷所致。原发性免疫缺陷单基因病具有孟德尔遗传性,影响免疫系统,导致多器官发病,并可能影响胃肠系统。原发性免疫缺陷单基因病不同于 "纯 "IBD,后者主要影响胃肠道,肠外症状较轻。自首次被描述以来,原发性免疫缺陷单基因病虽然罕见,但因其显著的表型、难以及时诊断和特殊的治疗方法而日益受到关注。在本文中,我们简要回顾了原发性免疫缺陷单基因病,重点介绍了其临床病理特征,并更详细地探讨了由 IFIH1 基因突变引起的单基因病。我们将采用损伤组织学模式描述 4 例 IFIH1(一种参与干扰素通路缺陷的基因)患者的临床病理特征,从而证实有必要避免对 6 岁以下儿童进行 VEO-IBD 的组织学诊断。
{"title":"Clinicopathologic Features of Primary Immunodeficiency Monogenic Disease-related Very Early Onset Inflammatory Bowel Disease: Focus on Gastrointestinal Histologic Features in IFIH1 Mutations.","authors":"Luisa Santoro, Federica Grillo, Maria D'Armiento, Anna Maria Buccoliero, Michele Rocco, Jacopo Ferro, Alessandro Vanoli, Barbara Cafferata, Maria Cristina Macciomei, Claudia Mescoli, Mara Cananzi, Rita Alaggio, Matteo Fassan, Luca Mastracci, Paola Francalanci, Paola Parente","doi":"10.1097/PAP.0000000000000457","DOIUrl":"https://doi.org/10.1097/PAP.0000000000000457","url":null,"abstract":"<p><p>Very early onset inflammatory bowel disease (VEO-IBD) is a clinical term referring to IBD-like symptomatology arising in children younger than 6 years. VEO-IBD may be due to polygenic etiology in \"pure\" IBD (Crohn disease-CD and ulcerative colitis-UC), or it may be caused by primary immunodeficiency underlined by monogenic disease. Primary immunodeficiency monogenic diseases have a Mendelian inheritance and affect the immune system with multiorgan morbidity and possible effects on the gastrointestinal system. Primary Immunodeficiency monogenic diseases differ from \"pure\" IBD as the latter primarily affect the gastrointestinal tract with mitigated extraintestinal symptomatology. Since their first description, primary immunodeficiency monogenic diseases, although rare, have been the subject of increasing interest due to their dramatic phenotype, difficulty in reaching a timely diagnosis, and specific therapeutic approach. In this paper, we present a brief review of primary immunodeficiency monogenic diseases, focusing on to their clinicopathologic features as well as delving, in greater detail, into monogenic diseases caused by IFIH1 mutations. The clinicopathologic features of 4 patients with IFIH1, a gene involved in interferon pathway deficiency, will be described using a histologic pattern of damage approach confirming the need to avoid the histologic diagnosis of VEO-IBD in children younger than 6 years.</p>","PeriodicalId":7305,"journal":{"name":"Advances In Anatomic Pathology","volume":" ","pages":""},"PeriodicalIF":5.1,"publicationDate":"2024-08-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141974802","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
#PathX: #PathTwitter's Transformation and a Discussion on Different Social Media Platforms Used by Pathologists in 2024. #PathX: #PathTwitter的转型以及2024年病理学家使用的不同社交媒体平台的讨论。
IF 6.7 2区 医学 Q1 PATHOLOGY Pub Date : 2024-07-01 Epub Date: 2023-12-04 DOI: 10.1097/PAP.0000000000000424
Casey P Schukow, Lavisha S Punjabi, Fadi W Abdul-Karim

#PathTwitter is a well-known virtual community that has historically been positive for pathologists, trainees, and medical students worldwide to communicate, collaborate, and connect for free. However, in 2023, the popular social media platform Twitter (parent company: X Corp.) transitioned to "X" and, with this, #PathTwitter evolved into #PathX. Although the overall user experience of X and Twitter has not changed significantly, this transition brought much anecdotal hesitancy from the online virtual pathology community early on. Thus, the purpose of this review is to discuss the background of Twitter's importance in pathology, the implications of this transition to the online pathology community, current views from this community regarding Twitter versus X, and to provide an overview of pertinent changes in the platform, as well as of different popular social media platforms that may be used by pathologists in 2024.

#PathTwitter是一个著名的虚拟社区,历史上一直是世界各地的病理学家、实习生和医学院学生免费交流、合作和联系的积极场所。然而,在2023年,流行的社交媒体平台Twitter(母公司:X Corp.)转变为“X”,因此,#PathTwitter演变为#PathX。尽管X和Twitter的整体用户体验并没有显著改变,但这种转变在早期引起了在线虚拟病理社区的许多传闻性犹豫。因此,本综述的目的是讨论Twitter在病理学中的重要性背景,这种转变对在线病理学社区的影响,该社区关于Twitter与X的当前观点,并概述该平台的相关变化,以及2024年病理学家可能使用的不同流行社交媒体平台。
{"title":"#PathX: #PathTwitter's Transformation and a Discussion on Different Social Media Platforms Used by Pathologists in 2024.","authors":"Casey P Schukow, Lavisha S Punjabi, Fadi W Abdul-Karim","doi":"10.1097/PAP.0000000000000424","DOIUrl":"10.1097/PAP.0000000000000424","url":null,"abstract":"<p><p>#PathTwitter is a well-known virtual community that has historically been positive for pathologists, trainees, and medical students worldwide to communicate, collaborate, and connect for free. However, in 2023, the popular social media platform Twitter (parent company: X Corp.) transitioned to \"X\" and, with this, #PathTwitter evolved into #PathX. Although the overall user experience of X and Twitter has not changed significantly, this transition brought much anecdotal hesitancy from the online virtual pathology community early on. Thus, the purpose of this review is to discuss the background of Twitter's importance in pathology, the implications of this transition to the online pathology community, current views from this community regarding Twitter versus X, and to provide an overview of pertinent changes in the platform, as well as of different popular social media platforms that may be used by pathologists in 2024.</p>","PeriodicalId":7305,"journal":{"name":"Advances In Anatomic Pathology","volume":" ","pages":"275-277"},"PeriodicalIF":6.7,"publicationDate":"2024-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138476560","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Modernizing Forensic Pathology Education on TikTok: Lessons Learned on this "Social Media Frontier". TikTok 上的法医病理学教育现代化:在 "社交媒体前沿 "吸取的经验教训。
IF 6.7 2区 医学 Q1 PATHOLOGY Pub Date : 2024-07-01 Epub Date: 2024-02-05 DOI: 10.1097/PAP.0000000000000437
Casey P Schukow, Meredith K Herman, Julia Kochanowski, Patrick A Hansma
{"title":"Modernizing Forensic Pathology Education on TikTok: Lessons Learned on this \"Social Media Frontier\".","authors":"Casey P Schukow, Meredith K Herman, Julia Kochanowski, Patrick A Hansma","doi":"10.1097/PAP.0000000000000437","DOIUrl":"10.1097/PAP.0000000000000437","url":null,"abstract":"","PeriodicalId":7305,"journal":{"name":"Advances In Anatomic Pathology","volume":" ","pages":"278-280"},"PeriodicalIF":6.7,"publicationDate":"2024-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139680557","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Advances In Anatomic Pathology
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1